Literature DB >> 18620875

Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.

J R Ellis1, V L Villemagne, P J Nathan, R S Mulligan, S J Gong, J G Chan, J Sachinidis, G J O'Keefe, K Pathmaraj, K A Wesnes, G Savage, C C Rowe.   

Abstract

Neuronal nicotinic acetylcholine receptors (nAChRs) are critical for higher order cognitive processes. Post-mortem studies suggest reductions in nAChRs (particularly the alpha(4)beta(2) subtype) with ageing and in Alzheimer's disease (AD). This study aimed to; (1) quantify nAChR distribution in vivo with 2-[18F]fluoro-A-85380 (2-FA) in 15 early AD patients compared to 14 age-matched, healthy controls (HC) and (2) correlate nAChR distribution with cognitive performance in both groups. All participants were non-smokers and underwent cognitive testing along with a dynamic PET scan after injection of 200 MBq of 2-FA. Brain regional 2-FA binding was assessed through a simplified estimation of Distribution Volume (DV(S)). The AD group differed significantly from HC on all cognitive measures employed, with impairments on measures of attention, working memory, language, executive function, visuospatial ability, verbal learning and verbal memory (p<.05). Contrary to post-mortem data this study found no evidence of in vivo nAChR loss in early AD despite significant cognitive impairment. Furthermore, no correlation between nAChR and cognitive performance was found for either group. The findings of the current study suggest preservation of nAChRs early in AD supporting previous studies. It is possible that while the clinical 2-FA PET method described here may be insensitive in detecting changes in early AD, such changes may be detected in more advanced stages of the illness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18620875     DOI: 10.1016/j.nlm.2008.05.006

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  19 in total

1.  Minimally invasive input function for 2-18F-fluoro-A-85380 brain PET studies.

Authors:  Paolo Zanotti-Fregonara; Renaud Maroy; Marie-Anne Peyronneau; Régine Trebossen; Michel Bottlaender
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-10       Impact factor: 9.236

Review 2.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

3.  Quantitative Molecular Imaging of Neuronal Nicotinic Acetylcholine Receptors in the Human Brain with A-85380 Radiotracers.

Authors:  Shahrdad Lotfipour; Mark Mandelkern; Arthur L Brody
Journal:  Curr Med Imaging Rev       Date:  2011-05-01

4.  Imaging changes in synaptic acetylcholine availability in living human subjects.

Authors:  Irina Esterlis; Jonas O Hannestad; Frederic Bois; R Andrew Sewell; Rachel F Tyndale; John P Seibyl; Marina R Picciotto; Marc Laruelle; Richard E Carson; Kelly P Cosgrove
Journal:  J Nucl Med       Date:  2012-11-15       Impact factor: 10.057

Review 5.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

6.  Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography.

Authors:  Kai Kendziorra; Henrike Wolf; Philipp Mael Meyer; Henryk Barthel; Swen Hesse; Georg Alexander Becker; Julia Luthardt; Andreas Schildan; Marianne Patt; Dietlind Sorger; Anita Seese; Herman-Josef Gertz; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-11       Impact factor: 9.236

7.  Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.

Authors:  J R Ellis; P J Nathan; V L Villemagne; R S Mulligan; T Saunder; K Young; C L Smith; J Welch; M Woodward; K A Wesnes; G Savage; C C Rowe
Journal:  Psychopharmacology (Berl)       Date:  2008-10-24       Impact factor: 4.530

8.  Imaging of cerebral α4β2* nicotinic acetylcholine receptors with (-)-[(18)F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain.

Authors:  A T Hillmer; I Esterlis; J D Gallezot; F Bois; M Q Zheng; N Nabulsi; S F Lin; R L Papke; Y Huang; O Sabri; R E Carson; K P Cosgrove
Journal:  Neuroimage       Date:  2016-07-15       Impact factor: 6.556

9.  Clinical Perspective and Recent Development of PET Radioligands for Imaging Cerebral Nicotinic Acetylcholine Receptors.

Authors:  Andrew G Horti; Dean F Wong
Journal:  PET Clin       Date:  2009-01-01

Review 10.  Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography.

Authors:  Andrew G Horti; Yongjun Gao; Hiroto Kuwabara; Robert F Dannals
Journal:  Life Sci       Date:  2009-03-18       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.